Svas Biosana Statistics

Total Valuation

Svas Biosana has a market cap or net worth of EUR 39.41 million. The enterprise value is 69.77 million.

Market Cap	39.41M
Enterprise Value	69.77M

Important Dates

The next estimated earnings date is Monday, April 14, 2025.

Earnings Date	Apr 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Svas Biosana has 5.40 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	5.40M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	6.35%
Owned by Institutions (%)	9.98%
Float	1.95M

Valuation Ratios

The trailing PE ratio is 7.23 and the forward PE ratio is 6.82.

PE Ratio	7.23
Forward PE	6.82
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	0.82
P/FCF Ratio	17.65
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.05, with an EV/FCF ratio of 31.25.

EV / Earnings	12.80
EV / Sales	0.56
EV / EBITDA	5.05
EV / EBIT	7.49
EV / FCF	31.25

Financial Position

The company has a current ratio of 1.93, with a Debt / Equity ratio of 1.08.

Current Ratio	1.93
Quick Ratio	1.37
Debt / Equity	1.08
Debt / EBITDA	4.60
Debt / FCF	28.45
Interest Coverage	2.07

Financial Efficiency

Return on equity (ROE) is 9.45% and return on invested capital (ROIC) is 4.99%.

Return on Equity (ROE)	9.45%
Return on Assets (ROA)	3.80%
Return on Capital (ROIC)	4.99%
Revenue Per Employee	378,559
Profits Per Employee	16,674
Employee Count	323
Asset Turnover	0.81
Inventory Turnover	2.82

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -3.10% in the last 52 weeks. The beta is 0.83, so Svas Biosana's price volatility has been lower than the market average.

Beta (5Y)	0.83
52-Week Price Change	-3.10%
50-Day Moving Average	7.01
200-Day Moving Average	7.68
Relative Strength Index (RSI)	64.12
Average Volume (20 Days)	1,696

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Svas Biosana had revenue of EUR 123.79 million and earned 5.45 million in profits.

Revenue	123.79M
Gross Profit	33.60M
Operating Income	9.31M
Pretax Income	7.07M
Net Income	5.45M
EBITDA	13.80M
EBIT	9.31M
Earnings Per Share (EPS)	n/a

Full Income Statement

Balance Sheet

The company has 33.16 million in cash and 63.52 million in debt, giving a net cash position of -30.36 million or -5.62 per share.

Cash & Cash Equivalents	33.16M
Total Debt	63.52M
Net Cash	-30.36M
Net Cash Per Share	-5.62
Equity (Book Value)	58.93M
Book Value Per Share	n/a
Working Capital	55.63M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 6.12 million and capital expenditures -3.89 million, giving a free cash flow of 2.23 million.

Operating Cash Flow	6.12M
Capital Expenditures	-3.89M
Free Cash Flow	2.23M
FCF Per Share	0.41

Full Cash Flow Statement

Margins

Gross margin is 27.15%, with operating and profit margins of 7.52% and 4.40%.

Gross Margin	27.15%
Operating Margin	7.52%
Pretax Margin	5.71%
Profit Margin	4.40%
EBITDA Margin	11.15%
EBIT Margin	7.52%
FCF Margin	1.80%

Dividends & Yields

Svas Biosana does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	29.35%
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	n/a
FCF Yield	5.67%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Svas Biosana has an Altman Z-Score of 1.83. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.83
Piotroski F-Score	n/a